24th Conference on Retroviruses and Opportunistic Infections (CROI 2017), 13-16 February 2017, Seattle

27 February 2017. Related: Conference reports, Conference index, CROI 24 (Retrovirus) 2017.

The 24th Conference on Retroviruses and Opportunistic Infections (CROI 2017) was held in Seattle from 13-16 February 2017.

More than 4000 researchers and health workers (and a good inclusion of community activists) worked through more than 1000 studies presented at the meeting.

Luckily, CROI supports broad open access to the conference materials online, including comprehensive webcasts of all oral presentations – available immediately after each session.

The programme for the meeting and abstract book – and nearly all posters – are now online as PDF files.

http://www.croiconference.org/electronic-materials

The searchable abstracts database links directly to PDF files for most posters.

http://www.croiconference.org/abstracts/search-abstracts

CROI is one of the leading scientific HIV meetings. But despite the last minute reversal of the proposed US travel restrictions, many delegates were suggesting that if similar entry restrictions are reimposed, then international medical conferences should perhaps not be held in the US and that CROI could be moved to Mexico or Canada.

This detracts nothing from the leading work by IAS-USA and US scientists. It is a way to refuse to normalise racist policies that exclude global inclusion in medical conferences.

And the exciting news: there was much to report.

The following reports are in this issue.

• Pharmacokinetics and full phase 2 results for bictegravir, a new integrase inhibitor
• New NNRTI doravirine is non-inferior to darunavir/r in phase 3 treatment naive study
• NRTI GS-9131 resurfaces at CROI 2017: in vitro sensitivity to nuke-resistant HIV
• Dolutegravir exposure increases when fixed dose combination tablets are crushed
• Pharmacokinetics, safety and efficacy of dolutegravir in very young children
• Efavirenz, tenofovir and emtricitabine associated with fewest adverse birth outcomes in Botswana
• Adverse pregnancy outcomes and risk factors in the PROMISE trial
• Women on lopinavir/ritonavir-based regimens at conception at higher risk of preterm delivery in UK study
• No increase in adverse birth outcomes with maternal TDF/FTC in US study
• Dolutegravir monotherapy studies stopped due to integrase resistance: dual therapy studies continue
• No evidence of accelerated brain ageing in HIV positive people on effective ART
• Acute infection with wild-type HIV on PrEP with good drug levels
• Fit for purpose: antiretroviral treatment optimisation (Feb 2017)
• Seattle-lite: pre-conference workshops – watch online